Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Patients With Alzheimer's Disease: A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre Study of 12 Weeks
ORM-12741, developed by Orion Corporation in collaboration with Janssen Pharmaceuticals, targets agitation and aggression symptoms in Alzheimer's disease, a significant unmet need in the market. The Alzheimer's disease therapeutics market is projected to grow substantially, driven by increasing prevalence and demand for effective treatments. The competitive landscape includes established therapies like cholinesterase inhibitors and memantine, but there remains a gap for targeted neuropsychiatric symptom management. Successful outcomes from this trial could position ORM-12741 as a novel treatment option, potentially enhancing Orion's portfolio and market share in the neurodegenerative disease space.
Indication: Alzheimer's Disease
Modality: small molecule
Target: Alpha-2C adrenoceptor (AR)
Sponsor: Orion Corporation, Orion Pharma
Source URL: ClinicalTrials.gov
Source updated: Feb 15, 2018
Ingested: Jun 13, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Alpha-2C adrenoceptor (AR)
View original source fields
Condition raw: Alzheimer's Disease
Condition normalized: Alzheimer's Disease
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Alpha-2C adrenoceptor (AR)
Target normalized: Alpha-2C adrenoceptor (AR)